| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 0.70 | 2.38 | 4.17 | 6.46 | 10.69 | 4.12 | 3.35 | 4.05 | 10.60 | 5.18 | — |
| Quick Ratio | 0.70 | 2.38 | 4.17 | 6.46 | 10.69 | 4.12 | 3.35 | 4.05 | 10.60 | 5.18 | — |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -294.78% | -115.61% | -228.43% | -146.75% | -59.59% | -173.96% | -183.01% | -160.95% | -47.29% | 16.21% | — |
| ROA | -206.44% | -101.11% | -14.84% | -124.18% | -53.97% | -129.47% | -110.94% | -104.07% | -42.90% | -82.30% | — |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Book Value / Share | 0.66 | 3.03 | 1.50 | 4.10 | 9.89 | 0.35 | 0.65 | 1.33 | 6.42 | -260.20 | — |
Rein Therapeutics Inc. is a biotechnology company dedicated to developing novel therapies for life-threatening diseases. The primary focus of the company lies in exploring advanced gene editing technologies to create treatments that address unmet clinical needs. Rein Therapeutics Inc. is heavily involved in research and development efforts, often collaborating with leading institutions and pharmaceutical firms to drive innovation in the biotech sector. Its groundbreaking work impacts various fields, particularly in genetic disorders, oncology, and infectious diseases. With headquarters based in a prominent biotech hub, Rein Therapeutics Inc. plays a significant role in the advancement of personalized medicine, delivering potentially transformative therapies to the market. As a publicly traded company, it attracts attention from a diverse range of investors and stakeholders interested in cutting-edge healthcare solutions.